Cargando…

RRM1 expression and the clinicopathological characteristics of patients with non-small cell lung cancer treated with gemcitabine

BACKGROUND: The usefulness of ribonucleotide reductase catalytic subunit M1 (RRM1) for predicting the therapeutic effects of gemcitabine-containing chemotherapy in patients with non-small cell lung cancer (NSCLC) remains controversial. RRM1-positive patients show unique clinicopathological features....

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Ying, Huang, Ying, Chen, Dong-Ming, Wu, Chao, Leng, Qiu-Ping, Wang, Wen-Yi, Deng, Ming-Qin, Zhao, Yan-Xia, Yang, Xiao-Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135431/ https://www.ncbi.nlm.nih.gov/pubmed/30237724 http://dx.doi.org/10.2147/OTT.S162667

Ejemplares similares

ERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and/or gemcitabine
por: Ulker, Mehmet, et al.
Publicado: (2015)

Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients
por: Boukovinas, Ioannis, et al.
Publicado: (2008)

Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine
por: Jørgensen, Charlotte LT, et al.
Publicado: (2013)

Expression of RRM1 and its association with resistancy to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma
por: Zhao, Li-Ping, et al.
Publicado: (2012)

RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin
por: Chun, Jung Won, et al.
Publicado: (2021)

RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy
por: Yang, Zhenxing, et al.
Publicado: (2019)

RRM1 single nucleotide polymorphism -37C→A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy
por: Dong, Song, et al.
Publicado: (2010)

Independent prognostic implications of RRM2 in lung adenocarcinoma
por: Ma, Chao, et al.
Publicado: (2020)

RRM1 *151A>T, RRM1 ‐756T>C, and RRM1 ‐585T>Gis associated with increased susceptibility of lung cancer in Chinese patients
por: Xu, Xiao‐Ling, et al.
Publicado: (2016)

Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2)
por: Xia, Guanggai, et al.
Publicado: (2017)

Relevance of ERCC1, RRM1 and BRCA1 in surgically treated non-small cell lung cancer patients
por: Pesta, Martin, et al.
Publicado: (2014)

Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells
por: Kato, Tomotaka, et al.
Publicado: (2021)

RRM1 is mediated by histone acetylation through gemcitabine resistance and contributes to invasiveness and ECM remodeling in pancreatic cancer
por: Ono, Hiroaki, et al.
Publicado: (2023)

A Kinome Screen Identifies Checkpoint Kinase 1 (CHK1) as a Sensitizer for RRM1-Dependent Gemcitabine Efficacy
por: Zhou, Jun, et al.
Publicado: (2013)

Clinical observation of docetaxel or gemcitabine combined with cisplatin in the chemotherapy after surgery for stage II–III non-small cell lung cancer
por: Chen, Qiu-Qiang, et al.
Publicado: (2015)

The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient
por: Mlak, R., et al.
Publicado: (2015)

MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy
por: Lu, Huimin, et al.
Publicado: (2019)

Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy
por: Leng, Xue-Feng, et al.
Publicado: (2012)

RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin
por: Muñoz-Montaño, Wendy, et al.
Publicado: (2021)

Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells
por: Zhang, Xia, et al.
Publicado: (2021)

Clinicopathologic Characteristics and Outcomes of Simultaneous Multiple Primary Lung Cancer
por: Liu, Ying, et al.
Publicado: (2021)

Expression levels of ERCC1 and RRM1 mRNA and clinical outcome of advanced non-small cell lung cancer
por: Jian-wei, Bi, et al.
Publicado: (2013)

MiR-202-3p inhibits the proliferation and metastasis of lung adenocarcinoma cells by targeting RRM2
por: Cao, Xiaowen, et al.
Publicado: (2022)

A missense mutation in RRM1 contributes to animal tameness
por: Dou, Mingle, et al.
Publicado: (2023)

Clinicopathological characteristics and prognosis of 77 cases with type 3 gastric neuroendocrine tumours
por: Li, Yuan-Liang, et al.
Publicado: (2020)

Clinicopathologic characteristics and diagnostic methods of RET rearrangement in Chinese non-small cell lung cancer patients
por: Feng, Junnan, et al.
Publicado: (2022)

Positive PD-L1 expression is predictive for patients with advanced EGFR wild-type non-small cell lung cancer treated with gemcitabine and cisplatin
por: Qiu, Yajuan, et al.
Publicado: (2019)

Response to First-Line Chemotherapy in Patients with Non-Small Cell Lung Cancer According to RRM1 Expression
por: Dong, Xiaopeng, et al.
Publicado: (2014)

Analysis of the Clinicopathologic Characteristics of Lung Adenocarcinoma With CTNNB1 Mutation
por: Zhou, Chao, et al.
Publicado: (2020)

NOVA1 expression is associated with clinicopathological characteristics and prognosis in patients with small cell lung cancer
por: Liu, Meixuan, et al.
Publicado: (2020)

Novel chimeric transcript RRM2-c2orf48 promotes metastasis in nasopharyngeal carcinoma
por: Han, Ping, et al.
Publicado: (2017)

Clinicopathological significance of oestrogen receptor expression in non-small cell lung cancer
por: Chen, Xiang-Qi, et al.
Publicado: (2016)

Structural basis of IMP3 RRM12 recognition of RNA
por: Jia, Min, et al.
Publicado: (2018)

Clinicopathologic characteristics and outcomes of Chinese patients with non‐small‐cell lung cancer and BRAF mutation
por: Ding, Xi, et al.
Publicado: (2017)

CD44 Gene Polymorphisms as a Risk Factor for Susceptibility and Their Effect on the Clinicopathological Characteristics of Lung Adenocarcinoma in Male Patients
por: Li, Ju-Pi, et al.
Publicado: (2020)

Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis
por: Zhang, Keqiang, et al.
Publicado: (2009)

Clinicopathological Characteristics and Prognostic Factors of Intrahepatic Biliary Cystadenocarcinoma
por: Xu, Ming-Yue, et al.
Publicado: (2015)

Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma
por: Shan, Ling, et al.
Publicado: (2015)

Former smokers with non‐small‐cell lung cancers: a comprehensive investigation of clinicopathologic characteristics, oncogenic drivers, and prognosis
por: Zheng, Shanbo, et al.
Publicado: (2016)

Primary adenoid cystic carcinoma of the lung: Clinicopathological features, treatment and results
por: HU, MING-MING, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_avgou8jug83r6qks6cn4kbsd2s